Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2) ]. - known or suspected malignancy of breast [see warnings and precautions (5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5) ]. - significant liver disease [see warnings and pre

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy.   limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2) ]. - known or suspected malignancy of breast [see warnings and precautions (5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5) ]. - significant liver disease [see warnings and p

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

northstar rxllc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension for use by females of reproductive potential to prevent pregnancy.   limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2) ]. - known or suspected malignancy of breast [see warnings and precautions (5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5) ]. - significant liver disease [see warnings and precautions (5

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

northstar rxllc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy.   limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2) ]. - known or suspected malignancy of breast [see warnings and precautions (5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5) ]. - significant liver disease [see warnings and p

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to medroxyprogesterone acetate. - known liver impairment or disease. - known or suspected pregnancy.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - medroxyprogesterone acetate, quantity: 150 mg - injection, suspension - excipient ingredients: macrogol 3350; polysorbate 80; sodium chloride; methyl hydroxybenzoate; propyl hydroxybenzoate; water for injections; hydrochloric acid; sodium hydroxide - carcinoma palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma.,endometriosis for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful.,contraception (ovulation suppression) for long-term prevention of pregnancy in women when administered at 3-month intervals.,since loss of bone mineral density (bmd) may occur in pre-menopausal women, who use medroxyprogesterone acetate long-term (greater than 2 years), women should be assessed before starting treatment for contraception or endometriosis, for the risk of osteoporosis. women under the age of 18 years may be at risk of failing to achieve their predicted peak bmd

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to medroxyprogesterone acetate. - known liver impairment or disease. - known or suspected pregnancy.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

afaxys pharma, llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension for use by females of reproductive potential to prevent pregnancy.   limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2) ]. - known or suspected malignancy of breast [see warnings and precautions (5.3) ]. - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5) ]. - significant liver disease [see warnings and precautions (5

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

remedyrepack inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate tablets, usp are indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. they are also indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets. medroxyprogesterone acetate is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen- or progesterone-dependent neoplasia. - active dvt, pe, or a history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions. - known anaphylactic reaction or angioedema to medroxyprogesterone acetate. - known liver impairment or disease. - known or suspected pregnancy.

Hoa Kỳ - Tiếng Anh - NLM (National Library of Medicine)

prasco laboratories - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate (mpa) injectable suspension, usp is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of mpa injectable suspension, usp is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)]. the use of mpa injectable suspension, usp is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to mpa injectable suspension, usp (medroxyprogesterone acetate or any of its other ingredients) [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)]